Literature DB >> 30444569

Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease.

Christian A Hudert1, Silvia Selinski2, Birgit Rudolph3, Hendrik Bläker3, Christoph Loddenkemper3, Ria Thielhorn4, Nikolaus Berndt5, Klaus Golka2, Cristina Cadenas2, Jörg Reinders2, Stephan Henning6, Philip Bufler6, Peter L M Jansen7, Hermann-Georg Holzhütter5, David Meierhofer4, Jan G Hengstler2, Susanna Wiegand1.   

Abstract

BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children and adolescents today. In comparison with adult disease, paediatric NAFLD may show a periportal localization, which is associated with advanced fibrosis. This study aimed to assess the role of genetic risk variants for histological disease pattern and severity in childhood NAFLD.
METHODS: We studied 14 single nucleotide polymorphisms (SNP) in a cohort of 70 adolescents with biopsy-proven NAFLD. Genotype was compared to an adult control cohort (n = 200) and analysed in relation to histological disease severity and liver tissue proteomics.
RESULTS: Three of the 14 SNPs were significantly associated with paediatric NAFLD after FDR adjustment, rs738409 (PNPLA3, P = 2.80 × 10-06 ), rs1044498 (ENPP1, P = 0.0091) and rs780094 (GCKR, P = 0.0281). The severity of steatosis was critically associated with rs738409 (OR=3.25; 95% CI: 1.72-6.52, FDR-adjusted P = 0.0070). The strongest variants associated with severity of fibrosis were rs1260326, rs780094 (both GCKR) and rs659366 (UCP2). PNPLA3 was associated with a portal pattern of steatosis, inflammation and fibrosis. Proteome profiling revealed decreasing levels of GCKR protein with increasing carriage of the rs1260326/rs780094 minor alleles and downregulation of the retinol pathway in rs738409 G/G carriers. Computational metabolic modelling highlighted functional relevance of PNPLA3, GCKR and UCP2 for NAFLD development.
CONCLUSIONS: This study provides evidence for the role of PNPLA3 as a determinant of portal NAFLD localization and severity of portal fibrosis in children and adolescents, the risk variant being associated with an impaired hepatic retinol metabolism.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  genetics; metabolic modelling; paediatric NAFLD; proteomics

Mesh:

Substances:

Year:  2018        PMID: 30444569     DOI: 10.1111/liv.14006

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  14 in total

Review 1.  Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.

Authors:  Simona Riccio; Rosa Melone; Caterina Vitulano; Pierfrancesco Guida; Ivan Maddaluno; Stefano Guarino; Pierluigi Marzuillo; Emanuele Miraglia Del Giudice; Anna Di Sessa
Journal:  World J Clin Pediatr       Date:  2022-03-23

Review 2.  Perspectives on youth-onset nonalcoholic fatty liver disease.

Authors:  Eduardo Castillo-Leon; Catherine E Cioffi; Miriam B Vos
Journal:  Endocrinol Diabetes Metab       Date:  2020-09-17

3.  Highlight report: General determinants of steatosis.

Authors:  Wiebke Albrecht
Journal:  EXCLI J       Date:  2018-12-19       Impact factor: 4.068

Review 4.  The Liver in Children With Metabolic Syndrome.

Authors:  Ebe D'Adamo; Valeria Castorani; Valerio Nobili
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-02       Impact factor: 5.555

5.  TGR5 regulates portal perfusion pressure of the liver.

Authors:  Ahmed Ghallab
Journal:  EXCLI J       Date:  2019-12-20       Impact factor: 4.068

Review 6.  Metabolic Signature of Hepatic Fibrosis: From Individual Pathways to Systems Biology.

Authors:  Ming-Ling Chang; Sien-Sing Yang
Journal:  Cells       Date:  2019-11-12       Impact factor: 6.600

Review 7.  New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease.

Authors:  Yu-Cheng Lin; Chi-Chien Wu; Yen-Hsuan Ni
Journal:  Front Pediatr       Date:  2020-12-09       Impact factor: 3.418

Review 8.  Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics.

Authors:  Anna Di Sessa; Simona Riccio; Emilia Pirozzi; Martina Verde; Antonio Paride Passaro; Giuseppina Rosaria Umano; Stefano Guarino; Emanuele Miraglia Del Giudice; Pierluigi Marzuillo
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

9.  rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis.

Authors:  Kevin Teo; Kushala W M Abeysekera; Leon Adams; Elmar Aigner; Quentin M Anstee; Jesus M Banales; Rajarshi Banerjee; Priyadarshi Basu; Thomas Berg; Pallav Bhatnagar; Stephan Buch; Ali Canbay; Sonia Caprio; Ankita Chatterjee; Yii-Der Ida Chen; Abhijit Chowdhury; Ann K Daly; Christian Datz; Dana de Gracia Hahn; Johanna K DiStefano; Jiawen Dong; Amedine Duret; Connor Emdin; Madison Fairey; Glenn S Gerhard; Xiuqing Guo; Jochen Hampe; Matthew Hickman; Lena Heintz; Christian Hudert; Harriet Hunter; Matt Kelly; Julia Kozlitina; Marcin Krawczyk; Frank Lammert; Claudia Langenberg; Joel Lavine; Lin Li; Hong Kai Lim; Rohit Loomba; Panu K Luukkonen; Phillip E Melton; Trevor A Mori; Nicholette D Palmer; Constantinos A Parisinos; Sreekumar G Pillai; Faiza Qayyum; Matthias C Reichert; Stefano Romeo; Jerome I Rotter; Yu Ri Im; Nicola Santoro; Clemens Schafmayer; Elizabeth K Speliotes; Stefan Stender; Felix Stickel; Christopher D Still; Pavel Strnad; Kent D Taylor; Anne Tybjærg-Hansen; Giuseppina Rosaria Umano; Mrudula Utukuri; Luca Valenti; Lynne E Wagenknecht; Nicholas J Wareham; Richard M Watanabe; Julia Wattacheril; Hanieh Yaghootkar; Hannele Yki-Järvinen; Kendra A Young; Jake P Mann
Journal:  J Hepatol       Date:  2020-08-31       Impact factor: 25.083

10.  Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Nader Salari; Niloufar Darvishi; Kamran Mansouri; Hooman Ghasemi; Melika Hosseinian-Far; Fateme Darvishi; Masoud Mohammadi
Journal:  BMC Endocr Disord       Date:  2021-06-19       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.